English 
Dutch 
French Batch vs. continuous processing in pharma
Compare batch vs. continuous pharmaceutical manufacturing. Explore advantages, limitations, hybrid approaches and key factors for process selection.
Two important approaches to pharmaceutical manufacturing
Batch and continuous processing are two important approaches to pharmaceutical manufacturing, each offering distinct advantages depending on process complexity, production volume, quality requirements and operational flexibility.
Batch and continuous processing are two important approaches to pharmaceutical manufacturing, each offering distinct advantages depending on process complexity, production volume, quality requirements and operational flexibility.
In batch processing, a fixed quantity of material is charged to a vessel, processed through a defined sequence of operations, and discharged as a discrete lot. The process has a clear start and end point, and the product is a bounded unit with a unique identity.
In continuous manufacturing, material flows through an integrated series of unit operations without interruption, feed streams enter, product exits, and the process operates at steady state for an extended duration. The concept of a “batch” is replaced by a time- or mass-defined segment of the continuous output stream, defined mathematically through residence time distribution (RTD) modelling rather than physical containment.
Both approaches are used in pharmaceutical research, API synthesis and drug product manufacturing. Understanding their differences is essential when selecting a manufacturing strategy that balances process efficiency, product quality, regulatory requirements and production flexibility.
Batch vs. continuous manufacturing: key differences
The main difference between batch and continuous pharmaceutical manufacturing lies in how materials move through the process and how production is organized.
Batch processing handles defined quantities of material in separate production cycles, while continuous manufacturing processes materials through an interconnected system over an extended operating period.
| Process characteristic | Batch processing | Continuous processing |
|---|---|---|
| Production mode | Discrete production lots | Continuous material flow |
| Process operation | Defined start and end point | Extended operation at steady state |
| Production flexibility | Well suited to multiple products and changing process requirements | Well suited to established, repeatable processes |
| Equipment configuration | Individual unit operations can be operated separately | Integrated unit operations with coordinated material flow |
| Process monitoring | In-process controls and batch-based quality assessments | Often integrates inline monitoring and PAT |
| Production scale | Increased through batch size, frequency or parallel equipment | Can be increased by extending run duration or adjusting validated operating conditions |
| Deviation management | Deviations can be assessed within a defined batch | Requires material tracking and appropriate diversion strategies |
| Typical applications | Complex API synthesis, clinical manufacturing and specialty products | High-volume production, selected API synthesis steps and solid dosage manufacturing |
Neither approach is universally superior. The most suitable manufacturing strategy depends on the chemistry, critical quality attributes, production requirements and intended product lifecycle.
Advantages of continuous manufacturing
Throughput and efficiency for high-volume products
For APIs or solid dosage forms manufactured at very high volumes, blockbuster generics, high-demand OTC actives, continuous manufacturing eliminates the non-productive time associated with batch charging, holding, cleaning between batches, and sequential quality review. A continuous direct compression line running at steady state can produce tablet output that would require multiple batch campaigns to match, with correspondingly lower labor intensity per unit produced.
Reduced equipment footprint
Continuous processes typically operate at higher throughput per unit volume than their batch equivalents, because material is not sitting idle during heating, cooling, or hold phases. This translates to smaller equipment, lower facility capital cost, and reduced energy consumption per kilogram of product, advantages that are significant at commercial scale for established molecules.
Real-time quality assurance through PAT
Continuous manufacturing is inherently aligned with process analytical technology. Because the process runs at steady state, inline sensors (as NMR), NIR for blend uniformity or API content, Raman for polymorph identity, FBRM for particle size, can monitor product quality continuously rather than at batch release endpoints.
Diversion logic can automatically exclude out-of-specification material from the product stream based on real-time sensor data, replacing end-product testing with continuous process monitoring. This is the model ICH Q8/Q9/Q10 and the PAT framework were designed to enable.
Supply chain resilience for critical medicines
The COVID-19 pandemic exposed the fragility of batch-based supply chains for essential medicines, where capacity is defined by the number of available batch campaigns rather than a continuously scalable flow rate. Continuous manufacturing, once validated, can respond to demand changes by adjusting run duration rather than scheduling additional batch campaigns, a meaningful advantage for pandemic preparedness and shortage mitigation.
Advantages of batch processing
Complex, multi-step synthesis with divergent chemistry
The strength of continuous manufacturing lies in processes where a single, well-characterized reaction or unit operation runs at steady state. Multi-step API synthesis, where each step involves different chemistry, different solvents, different temperature regimes, and potentially different reaction times, is far more difficult to integrate into a single continuous flow. Each step-to-step transition in a continuous synthesis requires compatible flow rates, residence times, and phase behaviors, constraints that frequently conflict with the individual optimum conditions for each reaction.
Flow chemistry, continuous processing at the individual reaction step level, is a genuine and growing capability in pharmaceutical synthesis, particularly for hazardous reactions (exothermic additions, reactions with explosive intermediates, ozone chemistry) where the small volumes in a flow reactor provide inherent safety advantages over batch. However, integrating multiple flow steps into a fully continuous synthesis train for a complex API remains technically demanding and is commercially applied only in specific cases.
Multi steps in flow chemistry are possible with Thalesnano’s modular concept. Batch processing at the step level, with flow chemistry inserted for specific high-risk or high-value transformations, is the prevalent hybrid model in current pharmaceutical API manufacturing.
Low-volume, high-value, and multi-product facilities
For CDMOs, clinical manufacturing organizations, and specialty API producers operating across a diverse product portfolio, continuous manufacturing lines are difficult to justify economically. A continuous manufacturing platform is optimized for one process; changeover to a different product requires re-validation of the entire integrated system, not merely equipment cleaning and batch record changeover.
The capital investment and process development burden of continuous manufacturing is most efficiently amortized over high-volume, long-lifecycle products, a profile that describes a minority of the pharmaceutical product portfolio.
Regulatory clarity and established precedent
Batch manufacturing is backed by decades of regulatory precedent, established guidance, and industry-wide expertise in batch record management, deviation handling, and change control. The regulatory pathway for a batch-manufactured API or drug product is well-understood and predictable.
Continuous manufacturing regulatory submissions, while increasingly supported by agency guidance, still require more extensive process characterization packages, RTD modelling, and control strategy justification. For molecules in early or mid-stage development, the regulatory risk premium of continuous manufacturing frequently does not justify the development investment relative to a well-controlled batch process.
Deviation management and batch containment
When a process deviation occurs in batch manufacturing, its scope is inherently contained within the affected lot. Investigation, impact assessment, and disposition decisions operate on a bounded production unit. In continuous manufacturing, a process excursion that is not detected in real time, or where the diversion logic fails, can affect a larger and less precisely bounded quantity of product.
The RTD-based “batch” definition in continuous manufacturing means that the material impacted by a deviation may not be physically separable from adjacent product without discarding a conservative window around the excursion. Robust continuous manufacturing control strategies address this through overlapping PAT monitoring and diversion systems, but the deviation containment logic is inherently more complex than the batch equivalent.
Hybrid manufacturing approaches
The binary framing of batch versus continuous is increasingly being replaced by hybrid process design, the deliberate combination of batch and continuous unit operations within a single manufacturing process, with each step assigned to the paradigm best suited to its technical requirements.
In API synthesis, this commonly means batch reactors for multi-step synthesis, with continuous flow microreactors inserted for specific steps involving hazardous chemistry, photochemistry, or reactions with short optimal residence times. In solid dosage form manufacturing, it means continuous blending and direct compression integrated with batch granulation or coating, where the granulation step benefits from batch-level control over water activity and granule growth kinetics.
This hybrid model is pragmatic and increasingly well-supported by regulatory guidance. FDA’s emerging framework for combination batch/continuous processes, and EMA’s reflection paper acknowledging partial continuous manufacturing, both provide a pathway for companies to adopt continuous operations selectively without committing to a fully integrated continuous line.
When is a hybrid approach beneficial?
A hybrid manufacturing strategy may be particularly relevant when individual processing steps have different operational requirements.
For example, a pharmaceutical API manufacturing process may involve multiple batch synthesis steps combined with a continuous flow reaction for a specific transformation. This allows manufacturers to introduce continuous processing where it provides a clear technical advantage while retaining the flexibility of batch operations elsewhere.
Hybrid manufacturing can therefore offer a practical transition between conventional batch production and fully integrated continuous manufacturing.
Batch vs. continuous processing: pharmaceutical applications
Batch and continuous manufacturing are applied across different stages of pharmaceutical development and production. The choice of processing method depends not only on production volume but also on the characteristics of the material and the requirements of each unit operation.
API synthesis and chemical reactions
Batch processing remains particularly relevant for complex, multi-step API synthesis involving different reaction conditions, solvents and intermediate processing requirements.
Continuous flow chemistry can offer advantages for selected reaction steps, particularly where precise residence time control, efficient heat transfer or reduced reaction volumes are beneficial.
For pharmaceutical manufacturers, this creates opportunities to combine conventional batch synthesis with targeted continuous flow operations.
Crystallization and solid isolation
Crystallization is an important step in many API manufacturing processes because it influences solid-state properties and subsequent processing.
Batch crystallization provides flexibility for controlling process conditions over defined production cycles. Continuous crystallization, where technically suitable, offers an alternative approach based on controlled material flow and continuous operation.
The selection of crystallization and solid isolation equipment should consider process requirements, material characteristics and the desired product quality attributes.
Solid dosage form manufacturing
Continuous manufacturing is increasingly relevant to solid dosage form production, particularly where integrated blending, feeding and compression operations can support sustained production.
Batch processing remains important where individual manufacturing stages require separate process control, intermediate assessment or flexible production scheduling.
Both approaches can be combined within hybrid manufacturing strategies.
Decision framework for process selection
The choice between batch, continuous, and hybrid process design for a given pharmaceutical manufacturing process is driven by a set of interlocking technical, regulatory, and commercial factors:
1. Production volume and product lifecycle
High-volume, long-lifecycle products with stable demand profiles are the strongest candidates for continuous manufacturing investment. Clinical-stage and specialty products with uncertain commercial trajectories are better served by flexible batch infrastructure.
2. Process chemistry complexity
Single-step or few-step processes with well-characterized kinetics and predictable steady-state behavior are amenable to continuous manufacturing. Multi-step synthesis with divergent chemistry, variable reaction times, and step-specific solvent and temperature requirements favors batch or hybrid approaches.
3. Facility and portfolio strategy
Dedicated single-product facilities can justify the capital and validation investment of continuous manufacturing. Multi-product facilities operating under shared equipment policies retain strong economic and operational reasons to remain batch-based.
4. Regulatory timeline and risk tolerance
For products targeting accelerated regulatory pathways or operating in markets with limited continuous manufacturing precedent, the additional regulatory development burden of continuous manufacturing must be weighed against the process performance benefits.
5. Quality risk profile
For APIs where polymorphic form, chiral purity, or genotoxic impurity control are critical quality attributes requiring intensive real-time monitoring, continuous manufacturing with integrated PAT may provide a stronger quality assurance framework than batch end-product testing. For processes where these attributes are reliably controlled by the chemistry itself, the additional PAT infrastructure of continuous manufacturing may add complexity without proportionate quality benefit.
Discuss your application with our Xperts
Our Xperts are happy to discuss your application and help you find the right solution.
FAQ
What is the difference between batch processing and continuous manufacturing?
Batch processing produces a fixed quantity of material within a defined start and end point, creating a discrete lot with its own identity and quality records. Continuous manufacturing operates uninterrupted, with materials continuously entering and exiting the process while product quality is monitored throughout production.
Which is better: batch processing or continuous manufacturing?
Neither approach is universally superior. Batch processing often offers greater flexibility, simpler changeovers, and established regulatory pathways. Continuous manufacturing can provide higher throughput, smaller equipment footprints, and real-time quality monitoring for high-volume products.
Why does continuous manufacturing require less equipment space?
Because material does not remain idle during holding, cooling, heating, or waiting periods, continuous systems can achieve higher production rates using smaller equipment volumes.
What is Process Analytical Technology (PAT)?
Process Analytical Technology (PAT) is a framework that uses analytical tools to monitor and control manufacturing processes in real time. Continuous manufacturing frequently relies on PAT to monitor product quality during production.
How does continuous manufacturing improve pharmaceutical supply chains?
Continuous manufacturing can respond to demand changes by extending production runs rather than scheduling additional batch campaigns. This can improve supply flexibility for essential medicines.
Is flow chemistry the same as continuous manufacturing?
Flow chemistry is a form of continuous processing applied to individual reaction steps. However, a complete pharmaceutical manufacturing process may combine multiple technologies and is not necessarily fully continuous.
Can batch and continuous processing be combined?
Yes. Many pharmaceutical manufacturers use hybrid manufacturing strategies that combine batch operations and continuous operations within the same production process.
What is hybrid pharmaceutical manufacturing?
Hybrid manufacturing combines batch and continuous unit operations, allowing each process step to use the manufacturing method that is technically most appropriate.
What is Residence Time Distribution (RTD)?
Residence Time Distribution is a mathematical approach used to describe how material moves through a continuous manufacturing system. RTD helps define product boundaries and supports traceability in continuous processes.